TLN-121 for relapsed or refractory non-Hodgkin lymphomas
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called TLN-121 for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have measurable disease (tumors that can be seen on scans).
- You must have one of the following lymphoma types that has returned or not responded to at least 2 prior treatments: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma grade 3b, or transformed lymphoma from follicular lymphoma.
- You may have follicular lymphoma grade 1-3a that needs treatment after at least 2 prior therapies.
- You may have certain types of peripheral T-cell lymphoma (PTCL) that have returned or not responded to at least 1 prior treatment.
- You must have high-grade B-cell lymphoma that has returned or not responded to at least 2 prior treatments.
- You must be able to perform daily activities with little or no help (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This trial tests a new drug called JNJ-95566692 for people with a type of lymphoma (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if the drug can help when no other standard options are available.
This Phase 1/2 study tests CT120 in people with B-cell non-Hodgkin’s lymphoma that has come back (relapsed) or did not respond well (refractory) to previous treatment. The goal is to find a safe dose and see whether it can shrink tumors.
This early-stage trial tests a new drug called CT1182 for B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatment. The study will measure how safe the drug is, how well it works, and how your body processes it.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
This trial tests a combination of three drugs for people with a slow-growing form of non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to see if this new combination can help shrink tumors or slow the disease.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.